Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells
暂无分享,去创建一个
C. Kang | So-jung Kim | Ga-Hee Ha | Sun-Hee Kim | Sunhee Kim | So-Jung Kim
[1] M. Todaro,et al. Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vγ9Vδ2 T Cell-Mediated Cytotoxicity , 2013, PloS one.
[2] S. Singhal,et al. Myeloid derived suppressor cells , 2013, Oncoimmunology.
[3] D. Shin,et al. Improvement of Antitumor Effect of Intratumoral Injection of Immature Dendritic Cells Into Irradiated Tumor by Cyclophosphamide in Mouse Colon Cancer Model , 2012, Journal of immunotherapy.
[4] Hiroaki Tanaka,et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.
[5] E. Jaffee,et al. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. , 2012, Cancer research.
[6] S. Albelda,et al. Tumor-associated neutrophils: friend or foe? , 2012, Carcinogenesis.
[7] I. Lowy,et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[8] S. Steinberg,et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[9] Thomas M Froesig,et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial , 2012, Cancer Immunology, Immunotherapy.
[10] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[11] M. Saif,et al. Novel agents in early phase clinical studies on refractory pancreatic cancer. , 2012, JOP : Journal of the pancreas.
[12] A. Schneeweiss,et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome , 2012, Cancer Immunology, Immunotherapy.
[13] J. Djeu,et al. Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy , 2012, Oncoimmunology.
[14] D. Schadendorf,et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.
[15] Y. Najjar,et al. Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms , 2011, European journal of immunology.
[16] K. Partanen,et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] S. Pascolo,et al. Gemcitabine depletes regulatory T‐cells in human and mice and enhances triggering of vaccine‐specific cytotoxic T‐cells , 2011, International journal of cancer.
[18] G. Shurin,et al. Regulatory dendritic cells: New targets for cancer immunotherapy , 2011, Cancer biology & therapy.
[19] T. Mussack,et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study , 2011, Cancer Immunology, Immunotherapy.
[20] Y. Chu,et al. CD4+Foxp3+ Regulatory T‐cell Impairment by Paclitaxel is Independent of Toll‐like Receptor 4 , 2011, Scandinavian journal of immunology.
[21] Alyssa D Gregory,et al. Tumor-associated neutrophils: new targets for cancer therapy. , 2011, Cancer research.
[22] Y. Kawakami,et al. The mechanisms of cancer immunoescape and development of overcoming strategies , 2011, International journal of hematology.
[23] Qingzhen Zhao,et al. A tritherapy combination of a fusion protein vaccine with immune‐modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice , 2011, International journal of cancer.
[24] L. Zitvogel,et al. Harnessing dendritic cells in cancer. , 2011, Seminars in immunology.
[25] J. Prieto,et al. Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells , 2011, The Journal of Immunology.
[26] Sun-Hee Kim,et al. Cyclophosphamide Potentiates the Antitumor Effect of Immunization with Injection of Immature Dendritic Cells into Irradiated Tumor , 2011, Immunological investigations.
[27] T. Tani,et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. , 2010, Oncology reports.
[28] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[29] D. Gilvary,et al. A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers , 2010, Clinical Cancer Research.
[30] Richard A. Flavell,et al. The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.
[31] David M. Mosser,et al. Exploring the full spectrum of macrophage activation , 2010, Nature Reviews Immunology.
[32] S. Ostrand-Rosenberg. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.
[33] J. Vincent,et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.
[34] Yusuke Nakamura,et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer , 2010, Cancer science.
[35] J. Rhee,et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders , 2010, Proceedings of the National Academy of Sciences.
[36] A. Dalgleish,et al. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses , 2009, British Journal of Cancer.
[37] G. Cheng,et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.
[38] P. Schellhammer,et al. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.
[39] S. Ferrini,et al. IL‐8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer , 2009, International journal of cancer.
[40] J. Landsberg,et al. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. , 2009, Cancer research.
[41] W. Leonard,et al. New insights into the regulation of T cells by γc family cytokines , 2009, Nature Reviews Immunology.
[42] Xuetao Cao,et al. Tumor-Educated CD11bhighIalow Regulatory Dendritic Cells Suppress T Cell Response through Arginase I1 , 2009, The Journal of Immunology.
[43] P. Allen,et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. , 2009, Cancer research.
[44] C. Divino,et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.
[45] R. Figlin,et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.
[46] B. Rini,et al. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.
[47] Masafumi Nakamura,et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. , 2009, Anticancer research.
[48] S. Howie,et al. Human Dendritic Cells Produce TGF-β1 under the Influence of Lung Carcinoma Cells and Prime the Differentiation of CD4+CD25+Foxp3+ Regulatory T Cells1 , 2009, The Journal of Immunology.
[49] M. Atkins,et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.
[50] M. Freschi,et al. Modulators of arginine metabolism support cancer immunosurveillance , 2009, BMC Immunology.
[51] P. Dahm,et al. Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma , 2008, Clinical Cancer Research.
[52] P. Dahm,et al. Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma1 , 2008, The Journal of Immunology.
[53] I. Borrello,et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.
[54] D. Vignali,et al. How regulatory T cells work , 2008, Nature Reviews Immunology.
[55] M. Manns,et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.
[56] L. Zitvogel,et al. The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.
[57] U. Hegde,et al. Presence of Low Dose of Fludarabine in Cultures Blocks Regulatory T Cell Expansion and Maintains Tumor-Specific Cytotoxic T Lymphocyte Activity Generated with Peripheral Blood Lymphocytes , 2008, Pathobiology.
[58] S. Mocellin,et al. Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines , 2008, Medicinal research reviews.
[59] Z. Werb,et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.
[60] M. Fishman,et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. , 2007, Cancer research.
[61] J. Sosman,et al. Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses , 2007, Clinical Cancer Research.
[62] S. Ko,et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. , 2007, Cancer research.
[63] B. Chauffert,et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.
[64] B. Tóth,et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. , 2007, International immunopharmacology.
[65] S. Abrams,et al. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy , 2007, Expert Reviews in Molecular Medicine.
[66] J. Califano,et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.
[67] Sun-Hee Kim,et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation , 2006, Experimental & Molecular Medicine.
[68] Ingo Fricke,et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. , 2006, Cancer research.
[69] P. Scherle,et al. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.
[70] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[71] C. Intrivici,et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Roman K. Thomas,et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. , 2005, Blood.
[73] L. Kaiser,et al. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.
[74] Michael Bitzer,et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. , 2005, Cancer research.
[75] S. Signoretti,et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.
[76] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[77] J. Schlom,et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.
[78] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[79] Lina Souan,et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. , 2004, Blood.
[80] C. N. Coleman,et al. External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing , 2004, Cancer Research.
[81] B. Chauffert,et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.
[82] D. Gabrilovich,et al. Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1 , 2004, The Journal of Immunology.
[83] Bin Yu,et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.
[84] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[85] D. Keskin,et al. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.
[86] G. Damonte,et al. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.
[87] J. Masferrer,et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.
[88] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[89] A. Raz,et al. Indomethacin Inhibits the Accumulation of Tumor Cells in Mouse Lungs and Subsequent Growth of Lung Metastases , 2000, Chemotherapy.
[90] Y. Kawahito,et al. Meloxicam inhibits the growth of non-small cell lung cancer. , 2000, Anticancer research.
[91] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[92] A. Castonguay,et al. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. , 1997, Carcinogenesis.
[93] D. Miles,et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[94] D. Berd,et al. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. , 1988, Cancer research.
[95] H. Maguire,et al. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.
[96] Glaser,et al. Regulation of specific cell-mediated cytotoxic response against SV40- induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice , 1979, The Journal of experimental medicine.
[97] J. Turk,et al. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity , 1974, Nature.
[98] Liquid Biopsies. Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.
[99] S. Sone,et al. Role of tyrosine kinase inhibitors in tumor immunology. , 2011, Immunotherapy.
[100] A. Liston,et al. Regulatory T Cells , 2011, Methods in Molecular Biology.
[101] E. Manuel,et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model , 2010, Cancer Immunology, Immunotherapy.
[102] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[103] K. Malmberg. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? , 2004, Cancer immunology, immunotherapy : CII.
[104] S. Gordienko. [Antitumor immunity]. , 1987, Voprosy onkologii.